Clinical Trial Update: ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) [Phase 2]

View source ↗

Summary

Phase 2 study UNICAB evaluating cabozantinib in various non-clear cell renal cell carcinoma subtypes after immunotherapy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma Type
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma
• Xp11 Translocation-related Renal Cell Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Status: COMPLETED